Login
Navigate Fool.com
Will INFI beat
the market?
Community Rating: 2 Stars: Unattractive

9.97 -0.53 (-5.05%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $10.51
Previous Close $10.50
Daily Range $9.90 - $10.52
52-Week Range $8.91 - $44.50
Market Cap $481.4M
P/E Ratio -3.98
Dividend (Yield) $0.00 (0.0%)
Volume 521,266
Average Daily Volume 689,962
Current FY EPS -$2.98

How do you think INFI
will perform against the market?

Top INFI Bull/Bear Pitches

 

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!

 

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

Why InterMune, Zulily, and Infinity Pharmaceuticals Are Today's 3 Best Stocks

Economic data pushes the S&P 500 marginally lower as InterMune, Zulily, and Infinity Pharmaceuticals all exploded higher.

Commit To Purchase Infinity Pharmaceuticals At $10, Earn 13.5% Annualized Using Options

Why Infinity Pharmaceuticals Inc. Shares Jumped

Shares of Infinity Pharmaceuticals jump by double-digits after reporting its fourth-quarter earnings results. Find out why investors would be wise to overlook the headline number and focus on this figure instead.

The Hidden Gems in Gilead Sciences' Pipeline

Gilead investors should look beyond the company’s antiviral portfolio and take a closer look at these hidden gems in its pipeline, which could shape the company’s long-term future.

Keep an Eye on These 3 Revolutionary Cancer Treatments in 2014

Let’s take a closer look at 3 revolutionary new cancer treatments from Inovio, Roche, ImmunoGen, and Gilead Sciences.

Synta Pharmaceuticals: 4 Key Investing Takeaways From 2013

Let’s take a look at 4 key investing takeaways from Synta’s volatile year, and how larger companies, like Infinity Pharmaceuticals, Roche, and GlaxoSmithKline, fit into the company’s growth prospects for 2014.

This Week in Biotech

A mixed bag of clinical studies, a highly-awaited FDA panel thumbs-up, and an unwelcome subpoena from the Department of Health and Human Services for one biotech company are this week's top stories.

Why Infinity Pharmaceuticals Inc. Shares Temporarily Spiked Higher

Infinity shares get a temporary boost after presenting a copious amount of preclinical and clinical data at the American Society of Hematology's annual meeting.

Mid-Day Market Update: Sysco Shares Rise Following Merger with US Foods; McDonald's Falls

Mid-Morning Market Update: Markets Rise; Covidien To Buy Given Imaging For $30/Share

See More INFI News...

Sector

Healthcare

Industry

Drugs

Infinity Pharmaceuticals, Inc. (INFI) Description

The Company's mission is to discover, develop, and deliver to patients medicines for the treatment of cancer and related conditions. Website: http://www.infi.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks